Vistagen Therapeutics (MEX:VTGN) Marketable Securities: MXN263.53 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:VTGN Vistagen Therapeutics Inc MEX:VTGN
29 GF Score
Price MXN10.65
GF Value MXN96.00
! 3 Warning Signs
View Full Analysis

What is Vistagen Therapeutics Marketable Securities?

Vistagen Therapeutics MEX:VTGN 29 Marketable Securities is MXN263.53 Mil as of Mar. 2026. GuruFocus rates MEX:VTGN with a GF Score™ of 29/100 and a GF Value™ of MXN96.00. The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Vistagen Therapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was MXN263.53 Mil.

Vistagen Therapeutics's annual Marketable Securities increased from Mar. 2024 (MXN0.00 Mil) to Mar. 2025 (MXN273.14 Mil) but then declined from Mar. 2025 (MXN273.14 Mil) to Mar. 2026 (MXN263.53 Mil).

Vistagen Therapeutics  (MEX:VTGN) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Vistagen Therapeutics Marketable Securities Related Terms

Vistagen Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Vistagen Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistagen Therapeutics Marketable Securities Chart

Vistagen Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 273.14 263.53

Vistagen Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 273.14 267.28 263.96 259.26 263.53
MEX:VTGN
29GF Score
Vistagen Therapeutics Inc MEX:VTGN
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistagen Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of MXN263.53 Mil mean?
Vistagen Therapeutics (MEX:VTGN) has a Marketable Securities of MXN263.53 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Vistagen Therapeutics and its competitors.
Is Vistagen Therapeutics' Marketable Securities too high?
Vistagen Therapeutics' current Marketable Securities is MXN263.53 Mil. Overall, Vistagen Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Vistagen Therapeutics' Marketable Securities compare to PSTV and KYNB?
Vistagen Therapeutics' Marketable Securities of MXN263.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Vistagen Therapeutics and its competitors. Vistagen Therapeutics's current Marketable Securities is MXN263.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistagen Therapeutics stock overvalued right now?
Vistagen Therapeutics (MEX:VTGN) has a current Marketable Securities of MXN263.53 Mil. The stock's GF Value™ is MXN96.00, compared to a current price of MXN10.65 — trading 88.9% below its estimated fair value. The current Marketable Securities is MXN263.53 Mil. Vistagen Therapeutics' overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Vistagen Therapeutics (MEX:VTGN), the current Marketable Securities is MXN263.53 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistagen Therapeutics (MEX:VTGN) Overvalued in 2026?

Based on GuruFocus' analysis, Vistagen Therapeutics stock appears to be undervalued. The current stock price of MXN10.65 is trading 88.9% below its estimated GF Value™ of MXN96.00.

Key valuation signals for MEX:VTGN:

  • Marketable Securities: MXN263.53 Mil
  • GF Value™: MXN96.00 vs. price of MXN10.65 (88.9% below fair value)
  • GF Score™: 29/100 with 3 warning signs

No single metric tells the full story. See the MEX:VTGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vistagen Therapeutics Business Description

Other Exchanges VTGN:USA
Address 343 Allerton Avenue, South San Francisco, CA, USA, 94080
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
29GF Score

Get the complete analysis for MEX:VTGN

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN10.65
Price
MXN96.00
GF Value